THE USE OF ISONICOTINYL HYDRAZINES IN THE TREATMENT OF TUBERCULOSIS
Authors: P. W. C.
Journal: Annals of Internal Medicine (1952)

Editorial1 July 1952THE USE OF ISONICOTINYL HYDRAZINES IN THE TREATMENT OF TUBERCULOSISP. W. C.P. W. C.Search for more papers by this authorAuthor, Article, and Disclosure Informationhttps://doi.org/10.7326/0003-4819-37-1-204 SectionsAboutPDF ToolsAdd to favoritesDownload CitationsTrack CitationsPermissions ShareFacebookTwitterLinkedInRedditEmail ExcerptAlthough great advances have been made in the past decade in the chemotherapy of tuberculosis, all the agents hitherto available have proved to be unsatisfactory in certain important respects. Of these streptomycin and its derivatives are by far the most effective. As is well known, these antibiotics will often arrest acute fulminant pulmonary infections as well as generalized (miliary) tuberculosis, which have been intractable to all other measures. Furthermore, the serious toxic effects of streptomycin have been markedly diminished by the current regimens utilizing occasional small doses (one gram two or three times a week), since it was found that...1 Hughes FJ: Combined intermittent regimens in the treatment of non-miliary pulmonary tuberculosis, Dis. Chest 21: 1-16, 1952. CrossrefMedlineGoogle Scholar2 Bernstein J: Chemotherapy of experimental tuberculosis. V. Isonicotinic acid hydrazide (Nydrazid) and related compounds, Am. Rev. Tuberc. 65: 357-364, 1952. MedlineGoogle Scholar3 GreenbergSchnitzer ERJ: Studies on the activity of hydrazine derivatives of isonicotinic acid in experimental tuberculosis of mice, Quart. Bull. Sea View Hosp. 13: 3-11, 1952. MedlineGoogle Scholar4 Greenberg E: On the lasting protective effect of hydrazine derivatives of isonicotinic acid in the experimental tuberculous infection of mice, Dis. Chest 21: 369-377, 1952. CrossrefMedlineGoogle Scholar5 SteenkenWolinsky WE: Antituberculous properties of hydrazides of isonicotinic acid (Rimifon, Marsilid), Am. Rev. Tuberc. 65: 365-375, 1952. MedlineGoogle Scholar6 Rubin B: Pharmacology of isonicotinic acid hydrazide (Nydrazid), Am. Rev. Tuberc. 65: 392-401, 1952. MedlineGoogle Scholar7 Benson WM: Pharmacologic and toxicologic observations on hydrazine derivatives of isonicotinic acid (Rimifon, Marsilid), Am. Rev. Tuberc. 65: 376-391, 1952. MedlineGoogle Scholar8 Elmendorf DF: The absorption, excretion, and short-term toxicity of isonicotinic acid hydrazide (Nydrazid) in man, Am. Rev. Tuberc. 65: 429-442, 1952. MedlineGoogle Scholar9 Robitzek EH: Chemotherapy of human tuberculosis with hydrazine derivatives of isonicotinic acid. Preliminary report of representative cases, Quart. Bull. Sea View Hosp. 13: 27-51, 1952. MedlineGoogle Scholar10 Robitzek EH: Hydrazine derivatives of isonicotinic acid (Rimifon, Marsilid) in the treatment of acute progressive caseous-pneumonic tuberculosis, Am. Rev. Tuberc. 65: 402-428, 1952. MedlineGoogle Scholar11 SelikoffRobitzek IJEH: Tuberculous chemotherapy with hydrazine derivatives of isonicotinic acid, Dis. Chest 21: 385-438, 1952. CrossrefMedlineGoogle Scholar12 McDermott W: Isonicotinic acid hydrazide in the treatment of tuberculosis in man, Reported at the sixty-fifth annual meeting of the Association of American Physicians, Atlantic City, N. J., May 6, 1952. Google Scholar13 Steenken W: Drug resistant tubercle bacilli from patients treated with isonicotinic acid hydrazides, J. A. M. A. 149: 187, 1952 (May 10, correspondence). CrossrefGoogle Scholar This content is PDF only. To continue reading please click on the PDF icon. Author, Article, and Disclosure InformationAffiliations: PreviousarticleNextarticle Advertisement FiguresReferencesRelatedDetails Metrics 1 July 1952Volume 37, Issue 1Page: 204-208KeywordsAntibioticsChemotherapyMiliary tuberculosisPulmonary diseasesStreptomycinTuberculosis ePublished: 1 December 2008 Issue Published: 1 July 1952 PDF downloadLoading ...